Pegaspargase (Oncaspar®) powder for solution for injection/infusion is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia in paediatric patients from birth to 18 years.
|NCPE Assessment Process||Complete|
|Rapid Review commissioned||05 February 2020|
|Rapid Review completed||13 March 2020|
|Rapid Review Outcome||A full HTA is not recommended. The NCPE recommends that pegaspargase (Oncaspar®) be considered for reimbursement*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.